Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta® (lefamulin), approved by the FDA in 2019 for both Oral and IV use, and CONTEPO (fosfomycin) for injection. The approval of CONTEPO has been impacted by FDA’s travel restrictions due to COVID-19. We have engaged with the FDA to determine next steps for CONTEPO. In July 2020, Nabriva Therapeutics entered into an exclusive agreement with Merck & Co. Inc., to promote and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and adolescent patients for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

SEC Filings

Filing date Description Form Filing Group View

Registration statement for certain foreign private issuers

F-1
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

Investor Contacts

E-mail: IR@nabriva.com